Menu
Back to Journals » Cancer Management and Research » Volume 13
Primary Squamous Cell Carcinoma of the Liver is Rare but Hostile: Case Series and Comprehensive Review of the Literature
Authors Xiao J, Ma L, Li J, Yin B, Liang J, Wang J
Received 11 November 2020
Accepted for publication 8 January 2021
Published 29 January 2021 Volume 2021:13 Pages 829—837
DOI https://doi.org/10.2147/CMAR.S290523
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Ahmet Emre Eşkazan
Junjuan Xiao, Lin Ma, Junwei Li, Beibei Yin, Jing Liang, Jun Wang
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, Jinan, People’s Republic of China
Correspondence: Jun Wang
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, No. 16766, Jingshi Road, Jinan 250014, People’s Republic of China
Tel +86-531-8926-8839
Email ggjun2005@126.com
Jing Liang
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University, No. 16766, Jingshi Road, Jinan 250014, People’s Republic of China
Tel +86-531-8926-9316
Email liangjing0531@163.com
Abstract: Primary squamous cell carcinoma (SCC) of the liver is an uncommon cancer type. Only dozens of such cases have been reported in the literature. We reviewed three cases with primary SCC of the liver in a single center from January 2013 to October 2019. One case was positive for hepatitis B infection and simultaneously diagnosed with sigmoid adenocarcinoma and liver cyst. The second patient presented with hepatolithiasis. The remaining one had no history of prior liver insult, hepatic infection or any pre-existing hepatic cysts. Two cases had a long survival of more than one year through chemotherapy, or radical surgery plus transarterial chemoembolization. We also found 25 patients with primary hepatic SCC in the Surveillance, Epidemiology and End Results (SEER) database from 1997 to 2016. The median age was 67 years (range 33– 87 years). The median overall survival and disease-specific survival were 7.7 months (range 0.0– 76.0 months) and 2.0 months (range 0.0– 20.0 months), respectively. Furthermore, patients receiving surgery had a longer median OS (20.0 versus 6.0 months, P = 0.016) and DSS (48.0 versus 8.0 months, P = 0.03) than those receiving palliative treatment. Only 20% of all cases survived for more than a year. Although primary SCC of the liver has an unfavorable prognosis, radical surgery and systematic treatment might be helpful for clinical management.
Keywords: primary squamous cell carcinoma, liver, survival, surgery, chemotherapy, SEER
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.